Topical imiquimod 5% as a treatment for localized genital Kaposi's sarcoma in an HIV-negative man: a case report

Fairley, Jessica; Denham, Ian; Yoganathan, Sabesan; Read, Tim

doi:10.1258/ijsa.2012.012074

Cited by 13 publications

(18 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If this reactivation leads to virus release, this in turn may stimulate tissue and tumor-resident antigen presenting cells [125]. At this point several cases of skin KS responding to topical treatment with imiquimod have been published, as have been treatment failures [126–128]. A systemic clinical trial has not been conducted.…”

Section: Update On Treatment Approachesmentioning

confidence: 99%

Diagnosis and Treatment of Kaposi Sarcoma

2017

View full text Add to dashboard Cite

Kaposi Sarcoma (KS) is the most common neoplasm of people living with HIV today. In Sub-Saharan Africa KS is among the most common cancers in men, overall. Not only HIV+ individuals present with KS; any immune compromised person infected with Kaposi Sarcoma-associated herpesvirus (KSHV) or human herpesvirus 8 is at risk: the elderly, children in KSHV-endemic areas, and transplant recipients. KS diagnosis is based on detection of the viral protein LANA in the biopsy, but not all cases of KS are the same or will respond to the same therapy. Standard KS therapy has not changed in 20 years, but newer modalities are on the horizon and will be discussed.

show abstract

Section: Update On Treatment Approachesmentioning

confidence: 99%

Diagnosis and Treatment of Kaposi Sarcoma

2017

View full text Add to dashboard Cite

show abstract

“…It has been found to be highly effective against KS in some case reports in the literature. [9][10][11][12][13][14][15][16][17] There is only 1 trial wherein imiquimod in KS was investigated for its antitumour activity, showing antitumour activity in 8 of 17 patients. 2 Our study is designed to evaluate the effect of imiquimod, which is distinguished from other local treatment methods by its at-home application, on classic KS lesions compared with cryotherapy, which is one of the most-used treatment methods for KS in our department.…”

Section: Introductionmentioning

confidence: 99%

Imiquimod 5% Cream Versus Cryotherapy in Classic Kaposi Sarcoma

et al. 2019

View full text Add to dashboard Cite

Background: Classic Kaposi sarcoma usually remains on the skin and has a slow progression; thus, local treatment methods are preferable. Imiquimod is an immunomodulatory agent with antiviral, antitumoural, and antiangiogenic properties that is expedient against Kaposi sarcoma. Objectives: We aimed to clarify whether imiquimod is effective on classic Kaposi sarcoma lesions by comparing imiquimod treatment with cryotherapy, which is the most-used treatment method in our department for this disease. Method: Patients with classic Kaposi sarcoma were included. All lesions of each patient were evaluated and measured by the blinded investigator considering infiltration and surface diameters. Then, lesions were categorized into 2 groups by the other investigator (nonblinded), and imiquimod 5% cream was administered 3 times per week without occlusion in 1 group. Cryotherapy was performed every 3 weeks in the other group. All lesions were reevaluated and measured at the end of 12 weeks by the blinded investigator. Initial and last measurements were compared between the treatment methods. Results: Fifty lesions of 8 patients were included in this study. Imiquimod and cryotherapy were applied to 26 and 24 lesions, respectively. At the end of the study, statistically significant decreases were detected in all scores between weeks 0 and 12 with both treatment methods. Mean percentages of change in scores were not significantly different between the methods. Conclusions: Based on a limited number of patients and lesions treated, we believe imiquimod may be a suitable option to use for the treatment of classic Kaposi sarcoma.

show abstract

“…87,88 Case reports have shown that imiquimod cream can be safe and effective in some patients with classic or transplant-associated Kaposi sarcoma. [89][90][91][92][93][94] In a single-center, open-label, phase I/II trial, 17 HIV-negative patients with Kaposi sarcoma received imiquimod 5% cream 3 times per week for 24 weeks. 95 The response rate was 47%.…”

Section: Topical Therapiesmentioning

confidence: 99%

AIDS-Related Kaposi Sarcoma, Version 2.2019

Reid

Suneja

Ambinder

et al. 2019

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

As treatment of HIV has improved, people living with HIV (PLWH) have experienced a decreased risk of AIDS and AIDS-defining cancers (non-Hodgkin’s lymphoma, Kaposi sarcoma, and cervical cancer), but the risk of Kaposi sarcoma in PLWH is still elevated about 500-fold compared with the general population in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AIDS-Related Kaposi Sarcoma provide diagnosis, treatment, and surveillance recommendations for PLWH who develop limited cutaneous Kaposi sarcoma and for those with advanced cutaneous, oral, visceral, or nodal disease.

show abstract

Topical imiquimod 5% as a treatment for localized genital Kaposi's sarcoma in an HIV-negative man: a case report

Cited by 13 publications

References 9 publications

Diagnosis and Treatment of Kaposi Sarcoma

Diagnosis and Treatment of Kaposi Sarcoma

Imiquimod 5% Cream Versus Cryotherapy in Classic Kaposi Sarcoma

AIDS-Related Kaposi Sarcoma, Version 2.2019

Contact Info

Product

Resources

About